

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Prostate cancer	Androgen receptor	<p><i>In vitro</i> and mouse studies identified a small molecule from <i>Geodia lindgreni</i> that inhibits androgen receptor and could treat prostate cancer. Screening and <i>in vitro</i> testing of marine sponge extracts identified a compound that inhibited the N-terminal domain of androgen receptor. In three human prostate cancer cell lines, the compound reduced androgen receptor-dependent proliferation compared with no treatment. In mice with androgen-sensitive and castration-resistant prostate cancer (CRPC) xenografts, the compound reduced tumor growth compared with no treatment. Ongoing work includes optimization of the lead compound.</p> <p>MDV3100, a triple-acting oral anti-androgen receptor from Medivation Inc. and Astellas Pharma Inc., is in Phase III testing to treat CRPC.</p> <p>Tokai Pharmaceuticals Inc.'s TOK-001, a selective androgen receptor modulator (SARM) and inhibitor of cytochrome P450 17 <math>\alpha</math>-hydroxylase/C17, 20 lyase (CYP17), is in Phase I/II testing to treat CRPC.</p> <p>Aragon Pharmaceuticals Inc.'s ARN-509, a small molecule that binds androgen receptor, is in preclinical development to treat CRPC.</p> <p><b>SciBX 3(24); doi:10.1038/scibx.2010.726</b>  <b>Published online June 17, 2010</b></p>	Patented by The University of British Columbia and the BC Cancer Agency; licensing status undisclosed	Andersen, R.J. <i>et al. Cancer Cell</i> ; published online June 13, 2010; doi:10.1016/j.ccr.2010.04.027 <b>Contact:</b> Marianne D. Sadar, BC Cancer Agency, Vancouver, British Columbia, Canada e-mail: <a href="mailto:msadar@bcgsc.ca">msadar@bcgsc.ca</a>